Work-Life Balance Matters More Than Pay for Many UK Doctors, Medscape Survey Reveals
LONDON--(BUSINESS WIRE)--New research from Medscape UK into doctors' mental and physical well-being, and their lives outside work, highlights growing concerns around the welfare of doctors.
The Medscape UK Wellness and Life Outside of Work Report 2025, released today, found a concerning 14% of doctors reported feeling burned out and depressed. Those under 45 were more likely to report feeling both.
Three out of four doctors polled attributed the cause of these mental health problems to their professional life.
Some 14% of all respondents admitted to using alcohol as a coping strategy, and 10% mentioned using prescription drugs.
Almost half (48%) of doctors said they would consider exchanging some of their pay for a better work-life balance.
Most doctors said they valued mental health, with just over half (53%) actively prioritising it. General Practitioners were more likely to do so than hospital specialists.
'These findings highlight how common mental health challenges are among doctors – and we know that long hours and heavy workloads are major contributing factors,' said Peter Russell, Managing editor, Medscape UK. 'No one should have to accept burnout as part of their job, especially not in healthcare, where the consequences can go beyond the individual doctor and affect patients and the wider healthcare system.'
Outside of work, two-thirds of doctors said they are happy with their life. Many cited hobbies such as reading, gardening, music, cooking, and sport as important for their mental well-being. However, 53% said a lack of time was the biggest challenge in maintaining close friendships outside of work.
Holidays are seen as important to happiness and good mental health by 54% of doctors. Despite this, younger doctors tend to take the least time off. Among those under 45, 28% reported taking only one to two weeks of annual leave a year, and 13% took less than one week.
'Doctors face considerable stress and emotional demands in their profession. These findings suggest that while doctors are aware of the importance of good mental health, they can sometimes fail to prioritise their own wellbeing. Protecting and maintaining the mental and emotional well-being of doctors should be a top priority – it's crucial for both doctors and the patients they serve.'
The Medscape UK Wellness and Life Outside of Work Report 2025 is available here:
About Medscape
Medscape is the leading source of clinical news, health information, and point-of-care tools for health care professionals. Medscape offers specialists, primary care physicians, and other health professionals the most robust and integrated medical information and educational tools. Medscape Education (medscape.org) is the leading destination for continuous professional development, consisting of more than 30 specialty-focused destinations offering thousands of free CME and CE courses and other educational programs for physicians, nurses, and other health care professionals.
Both Medscape and Medscape Education are part of WebMD Health Corp., an Internet Brands company.
About Medscape 2050
In 2025, Medscape marks its 30th anniversary, a milestone that highlights three decades of commitment to providing healthcare professionals with the latest medical news, clinical information, and educational resources. To commemorate this milestone, Medscape has launched Medscape 2050: The Future of Medicine, a dedicated hub on its platform that explores the future of medicine. This hub will be continually updated with a range of insights, videos and resources focused on the advancements shaping the medical landscape.
About WebMD Health Corp.
WebMD Health Corp., an Internet Brands company, is at the heart of the digital health revolution that is transforming the healthcare experience for consumers, patients, healthcare professionals, employers, health plans and health systems. Through public and private online portals, mobile platforms, and health-focused publications, WebMD delivers leading-edge content and digital services that enable and improve decision-making, support and motivate health actions, streamline and simplify the healthcare journey, and improve patient care.
The WebMD Health Network includes WebMD Health, Medscape, WebMD Ignite (encompassing Krames, The Wellness Network and Mercury Healthcare), Jobson Healthcare Information, MediQuality, Frontline, Vitals Consumer Services, Aptus Health, PulsePoint, The Wellness Network, SanovaWorks, MNG Health, MedicineNet, eMedicineHealth, RxList, OnHealth, Medscape Education, and other owned WebMD sites. WebMD ®, Medscape ®, CME Circle ®, Medpulse ®, eMedicine ®, MedicineNet ®, theheart.org ® and RxList ® are among the trademarks of WebMD Health Corp. or its subsidiaries.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
19 minutes ago
- Business Wire
Trustwise Introduces the First Trust Layer for Agentic AI
AUSTIN, Texas--(BUSINESS WIRE)-- Trustwise, the AI Security company, today introduced Harmony AI, the industry's first runtime trust layer and control tower designed for enterprises deploying fleets of generative and agentic AI systems. Harmony AI embeds 'trust as code' directly into AI systems, empowering CISOs, developers, and AI leaders to shield their AI deployments from security risks as they scale. Co-developed with leading financial and healthcare institutions over the past two years, Harmony AI delivers enterprise-grade security and control in production, achieving 90-100% runtime alignment with enterprise safety, compliance, and brand policies, detecting 40% more hallucinations and policy violations than baseline systems, and reducing AI operational costs and carbon emissions by 83% and 64%, respectively. 'Our mission at Health Innovation Network is to find, test, implement, and scale the best of responsible innovation in health. Partnering with Trustwise allows us to work with the providers in our region to deploy agentic AI systems with confidence, underpinned by a trust layer that meets the highest standards of safety, security, and compliance. This isn't just about protecting data, it's about protecting lives,' said Dr. Hatim Abdulhussein, CEO of Health Innovation Kent Surrey Sussex. Traditional Security Models Fail Against Agentic AI Threats Enterprise adoption of autonomous agents is exploding. Gartner predicts that 33% of enterprise software applications will include agentic AI, and at least 15% of day-to-day work decisions will be made autonomously through AI agents. Developer usage of agents is also surging, with 99% of developers surveyed by IBM exploring or building AI agents. However, the enterprise stack is not ready. AI agents act unpredictably, overspend, and leak data, amplifying chaos, cost, and compliance risk. They are the next insider threat: unmonitored, deeply embedded, and operating at machine speed. Anyone can build agents, from code writers to copilots, but few can secure and control them. Existing tools like observability and prompt filtering can't stop prompt injections, toolchain exploits, or message compromise that hijack agent behavior. Without AI-SPM, enterprises are flying blind. 'AI agents are transformative, but unshielded agents introduce a new class of insider threats,' said Manoj Saxena, CEO and founder of Trustwise. 'Just like human employees, they require oversight and runtime enforcement. Harmony AI provides the missing trust layer, securing digital workers at runtime while giving developers speed, security teams control, and enterprises the confidence to scale AI safely.' Harmony AI Shields Provide Modular Defense for AI Behavior Harmony AI delivers plug-and-protect security through six modular shields that secure and control both generative AI and agentic AI stacks across any model, agent, or cloud. Built for runtime by default and designed to scale, each of the following shields can operate independently or work together as a layered defense system, giving developers and security teams full visibility and control over AI behavior in real time: MCP Shield: Secures agent-tool execution using Model Context Protocols (MCP) to block tool misuse and unauthorized automation Prompt Shield: Prevents injection attacks, hallucinations, and off-policy outputs through dynamic prompt-level safeguards Compliance Shield: Aligns AI behavior with 17 global standards including ISO 42001, NIST Risk Management Framework, EU AI Act, HIPAA, and FCA Brand Shield: Maintains brand tone, persona, and use case discipline across all agent outputs Cost Shield: Reduces operating costs by intelligently routing between models, controlling token usage, and preventing recursive loops that drive budget explosions Carbon Shield: Reduces carbon footprint through energy-efficient model selection, carbon-aware scheduling, and real-time emission tracking aligned with ISO/IEC 21031:2024 SCI standards 'Developers aren't just securing text anymore, they're securing actions,' said Matthew Barker, head of AI research at Trustwise. 'That demands real-time controls that help both developers and security teams monitor how agents think, decide, and act. Harmony AI acts as a runtime shield, enforcing security and control directly in the decision loop and preventing drift before agents go off course.' Harmony AI Shields are powered by the proprietary Trustwise AI-SPM Engine, combining industry-specific red-teaming datasets, tuned small language models (SLMs) engineered for low-latency performance, synthetic personas, and more than 1,100 mapped controls from OWASP, ISO, NIST, and the EU AI Act. Award-Winning Technology Trustwise has earned industry-wide recognition for innovation, impact, and enterprise readiness. These accolades include: Fintech Leader 2024 by Hitachi Digital Services Winner of the 2024 A.I. Awards InfoWorld Technology of the Year 2024 in the AI and ML: Development category Most Innovative AI Product 2025 by theCUBE Technology Innovation Awards Tech Trailblazers 2024 award winner These honors reflect Trustwise's leadership in building the AI trust layer, delivering real-time security, compliance, and performance optimization for enterprise-grade generative and agentic AI systems. Built for Real-World AI Environments Harmony AI is live in production with top financial and healthcare enterprises, and currently offered in private preview to select Trustwise customers and OEM partners. It is built to integrate seamlessly with: Agent frameworks: LangGraph, AutoGen, CrewAI, and LangChain Foundation models: GPT-4o, Claude, Gemini, Llama 3, and Mistral Infrastructure: AWS, Azure, GCP, on-premises, and edge Additional Resources Book a free demo Learn more about Trustwise on the company blog Follow Trustwise on LinkedIn and YouTube About Trustwise Trustwise is an AI Security company specializing in securing and controlling the behavior of generative AI and agentic AI systems. Our software embeds 'trust as code' directly into AI systems to deliver precise AI Security Posture Management (AI-SPM) at runtime, keeping AI shielded from security risks, aligned with policies, and optimized for scale.
Business Wire
27 minutes ago
- Business Wire
Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 – 25, 2025
HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) ('Coya' or the 'Company'), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer Arun Swaminathan, Ph.D. will present at the iAccess Alpha Virtual Best Ideas Summer Conference on Tuesday, June 24, 2025. Dr. Swaminathan and Chief Financial Officer David Snyder will be meeting with investors on Wednesday, June 25, 2025. For more information about the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2025, or to register and schedule a one-on-one meeting with management, please visit the conference website at: The live and archived webcast will be accessible from the Company's website at under the Investor Relations section - Events and Presentations. About Coya Therapeutics, Inc. Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells ("Tregs") to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions, including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system. Coya's investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya's therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. For more information about Coya, please visit Forward-Looking Statements This press release contains "forward-looking" statements that are based on our management's beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our current and future financial performance, business plans and objectives, current and future clinical and preclinical development activities, the timing of clinical submissions to regulatory bodies including the FDA, timing and success of our ongoing and planned clinical trials and related data, the timing of announcements, updates and results of our clinical trials and related data, our ability to obtain and maintain regulatory approval, the potential therapeutic benefits and economic value of our product candidates, competitive position, industry environment and potential market opportunities. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but not limited to, those related to risks associated with the impact of COVID-19; the success, cost and timing of our product candidate development activities and ongoing and planned clinical trials; our plans to develop and commercialize targeted therapeutics; the progress of patient enrollment and dosing in our preclinical or clinical trials; the ability of our product candidates to achieve applicable endpoints in the clinical trials; the safety profile of our product candidates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations; development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approvals; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of the markets for our product candidates, and our ability to serve those markets; our commercialization, marketing and manufacturing capabilities and strategy; future agreements with third parties in connection with the commercialization of our product candidates; our expectations regarding our ability to obtain and maintain intellectual property protection; our dependence on third party manufacturers; the success of competing therapies or products that are or may become available; our ability to attract and retain key scientific or management personnel; our ability to identify additional product candidates with significant commercial potential consistent with our commercial objectives; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. Moreover, we operate in a very competitive and rapidly changing environment, and new risks may emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed herein may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Although our management believes that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or occur. We undertake no obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Yahoo
28 minutes ago
- Yahoo
Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 – 25, 2025
HOUSTON, June 18, 2025--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer Arun Swaminathan, Ph.D. will present at the iAccess Alpha Virtual Best Ideas Summer Conference on Tuesday, June 24, 2025. Event: iAccess Alpha Virtual Best Ideas Summer Conference Date: June 24, 2025 Time: 10:30am ET (presentation) Webcast: Dr. Swaminathan and Chief Financial Officer David Snyder will be meeting with investors on Wednesday, June 25, 2025. For more information about the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2025, or to register and schedule a one-on-one meeting with management, please visit the conference website at: The live and archived webcast will be accessible from the Company's website at under the Investor Relations section - Events and Presentations. About Coya Therapeutics, Inc. Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells ("Tregs") to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions, including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system. Coya's investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya's therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. For more information about Coya, please visit Forward-Looking Statements This press release contains "forward-looking" statements that are based on our management's beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our current and future financial performance, business plans and objectives, current and future clinical and preclinical development activities, the timing of clinical submissions to regulatory bodies including the FDA, timing and success of our ongoing and planned clinical trials and related data, the timing of announcements, updates and results of our clinical trials and related data, our ability to obtain and maintain regulatory approval, the potential therapeutic benefits and economic value of our product candidates, competitive position, industry environment and potential market opportunities. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but not limited to, those related to risks associated with the impact of COVID-19; the success, cost and timing of our product candidate development activities and ongoing and planned clinical trials; our plans to develop and commercialize targeted therapeutics; the progress of patient enrollment and dosing in our preclinical or clinical trials; the ability of our product candidates to achieve applicable endpoints in the clinical trials; the safety profile of our product candidates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations; development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approvals; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of the markets for our product candidates, and our ability to serve those markets; our commercialization, marketing and manufacturing capabilities and strategy; future agreements with third parties in connection with the commercialization of our product candidates; our expectations regarding our ability to obtain and maintain intellectual property protection; our dependence on third party manufacturers; the success of competing therapies or products that are or may become available; our ability to attract and retain key scientific or management personnel; our ability to identify additional product candidates with significant commercial potential consistent with our commercial objectives; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. Moreover, we operate in a very competitive and rapidly changing environment, and new risks may emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed herein may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Although our management believes that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or occur. We undertake no obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. View source version on Contacts Investor Contact David Snyder, CFOdavid@ CORE IR Bret Shapirobrets@ 561-479-8566 Media Contacts For Coya Therapeutics: Kati Waldenburgmedia@ 212-655-0924 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
